KRAS Biomarkers

GenFleet Therapeutics Cleared in Europe to Study KRAS, EGFR Inhibitor Combo in NSCLC Patients

Gritstone Bio, NCI Collaborate on Cancer Vaccine, Cell Therapy Combo Study in KRAS-Mutant Tumors

Hookipa Pharma to Submit IND for Phase I Immunotherapy Trial in KRAS-Mutated Cancers

Kenyan University Opens Clinical Trial Site for Roche's Investigational KRAS G12C Inhibitor

Amgen's Lumakras Sales Increased 58 Percent in Q4 2022

Verastem Oncology Plans for FDA Submission of Avutometinib-Defactinib Combo in Ovarian Cancer

Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment

Mirati Therapeutics' KRAS G12D Inhibitor Cleared by FDA to Begin Phase I/II Trial

Elicio Therapeutics to Merge With Angion Biomedica

METiS Inks Exclusive Licensing Agreement With Evopoint Biosciences for SOS1 Inhibitor

Frontier Medicines Selects KRAS G12C Inhibitor as Lead Development Candidate

FDA Approves Mirati's Krazati for Advanced KRAS-Mutated Lung Cancer 

Addario Lung Cancer Medical Institute Begins Study Exploring KRAS Inhibitor Resistance

Erasca Inks Deal With Pierre Fabre on ERAS-007, Braftovi Combo Study in Colorectal Cancer

AstraZeneca to Acquire Cell Therapy Firm Neogene Therapeutics

ElevateBio, Affini-T Partner on KRAS-Targeted Cell Therapy Development

Erasca to Study ERK Inhibitor With Pfizer's Ibrance in Tumors Harboring KRAS, NRAS Mutations

Roche Licenses Hookipa Pharma's KRAS-Targeted Immunotherapy